Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Dermatomyositis Clinical Trial

Official title:

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02466243
• Other study ID #: JBT101-DM-001
• Secondary ID: 116313R21AR06628
• Status: Terminated
• Phase: Phase 2
• Start date: June 2015
• Est. completion date: January 29, 2021

Study information

• Verified date: December 2022
• Source: Corbus Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.

Description:

Part A: An interventional, double-blind, randomized, placebo-control design will be used to test JBT-101 in about 22 eligible male or female subjects ≥ 18 and ≤ 70 years of age with moderate-to-severe active skin-predominant dermatomyositis. Part B: A one-year open-label design to test JBT-101 in subjects who completed Part A without permanent discontinuation of study product because of safety or tolerability reasons.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: January 29, 2021
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria (Part A):

• CDASI activity score = 14;
• No difficulty with lifting or walking, and no more than 1.5 x the upper limit of normal of creatine phosphokinase or aldolase;
• Failed at least 3 months treatment with hydroxychloroquine;
• Stable treatment for dermatomyositis for at least 28 days before Visit 1 (Day 1).

Inclusion Criteria (Part B):

• Completion of dosing in Part A without permanent discontinuation of study product because of safety or tolerability reasons

Exclusion Criteria (Part A and B):

• Significant diseases or conditions other than DM that may influence response to the study product or safety;
• Any one of the following values for laboratory tests at Screening:

1. A positive pregnancy test (or at Visit 1);

2. Hemoglobin < 10 g/dL;

3. Neutrophils < 1.0 x 10^9/L;

4. Platelets < 75 x 10^9/L;

5. Creatinine clearance < 50 ml/min according to modified Cockcroft-Gault equation;

6. Aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase > 2.5 x upper normal limit;

7. Total bilirubin = 1.5 x upper limit of normal.

• Any other condition that, in the opinion of the Principal Investigator, is clinically significant and may put the subject at greater safety risk, influence response to study product, or interfere with study assessments.

Related Conditions & MeSH terms

• Dermatomyositis

Intervention

Drug:
• JBT-101
Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84. Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE.
• Placebo
Part A: Once daily on Days 1-28, then twice daily on Days 29-84. Part B: Placebo twice daily on Days 1 - 365 of the OLE.

Locations

Country	Name	City	State
United States	University of Pennsylvania Perlman School of Medicine	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Corbus Pharmaceuticals Inc.	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) From Baseline in Part A.	The CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity, In the CDASI, DM skin disease activity is scored from 0 to 100 based on the physician's evaluation of erythema, scale, and erosion or ulceration at 15 anatomic locations as well as alopecia, Gottron's sign or papules on the hands, and periungual changes. A 5-point or greater decrease in the CDASI activity score indicates clinically relevant improvement based on statistical analysis using a receiver operating characteristic curve to maximize sensitivity and specificity	Part A: 84-day treatment period (Change from the Baseline CDSAI score at Day 84)
Primary	Number of Participants With Treatment Emergent Adverse Events as a Measure of Safety and Tolerability	Number of participants with treatment emergent adverse events were assessed as a measure of safety and tolerability	Part A: to Day 84
Secondary	Change in Patient-reported Outcomes From Baseline at 84 Days for Part A	LS mean (SE) change from baseline to Week 6 (Day 84) for lenabasum vs. placebo using a mixed model repeated measures analysis; The CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity and damage, In the CDASI, the Damage Score is scored from 0 to 32 based on the physician's evaluation of poikiloderma and calcinosis. 0 representing no damage and 32 representing the greatest level of damage.	Part A: 84-day treatment period